@entity68917 , approved in late 2014 in the United States and Japan for the treatment of @entity22 characterized by difficulty achieving and/or maintaining sleep, is a dual orexin receptor antagonist and the first drug in its class to reach the market. Its development followed from the 1998 discovery of orexins (also called hypocretins), excitatory neuropeptides originating from neurons in the hypothalamus involved in regulation of sleep and wake, feeding behavior and energy regulation, motor activity, and reward-seeking behavior. @entity68917 objectively improves sleep, shortening the time to achieve persistent sleep and reducing wake after sleep onset, although at approved doses ( <=20 mg) the benefit was subjectively assessed as modest. Its half-life of 12 hours is relatively long for a modern hypnotic; however, at approved doses ( <=20 mg) next-day sedation and driving impairment were much less apparent than at higher doses. @entity68917 is metabolized by the hepatic @entity5322 system and should be avoided in combination with strong @entity5322 inhibitors. Drug levels are higher in @entity1 and @entity28 @entity1 ; hence, dosing should be conservative in @entity28 @entity1 . Administration with food delays drug absorption and is not advised. No dose adjustment is needed for advanced age, @entity8 , or mild-to-moderate @entity409 . @entity68917 in contraindicated in @entity2724 and has not been studied in @entity1 . In alignment with the changes begun in 2013 in the labeling of other hypnotics, the United States Food and Drug Administration advises that the lowest dose effective to treat symptoms be used and that @entity1 be advised of the possibility of next-day impairment in function, including driving. Infrequent but notable side effects included @entity854 , @entity2726 , and suicidal ideation that were dose-related and reported to be mild. Given its mechanism of action, @entity2725 and rapid eye movement (REM) @entity146 could potentially occur in some @entity1 taking this medication.

Profile of @entity68917 in the management of XXXX .

@entity1 :: ('9606', 'Species') :: ['women', 'children', 'patients', 'people'] @entity8 :: ('MESH:D007674', 'Disease') :: ['renal impairment'] @entity2725 :: ('MESH:D002385', 'Disease') :: ['cataplexy'] @entity2726 :: ('MESH:D020188', 'Disease') :: ['sleep paralysis'] @entity28 :: ('MESH:D009765', 'Disease') :: ['obese'] @entity146 :: ('MESH:D001523', 'Disease') :: ['sleep behavior disorder'] @entity5322 :: ('1576', 'Gene') :: ['CYP3A'] @entity409 :: ('MESH:D008107', 'Disease') :: ['hepatic impairment'] @entity2724 :: ('MESH:D009290', 'Disease') :: ['narcolepsy'] @entity68917 :: ('MESH:C551624', 'Chemical') :: ['Suvorexant'] @entity854 :: ('MESH:D018376', 'Disease') :: ['abnormal dreams'] @entity22 :: ('MESH:D007319', 'Disease') :: ['insomnia']
@entity22 :: (MESH:D007319,Disease) :: ['insomnia']
